Retatrutide RT20 20mg*10vials

Retatropeptide RT20 20mg x 10 Vials

Product Overview

Retatropeptide RT20 is the top-tier highly potent triple-target receptor agonist peptide in the Retatropeptide series. As the final version of the GLP-1 and GIP and GCGR triple-target metabolic modulator, RT20 supports fully optimized molecular structure, ultra-high receptor binding activity, and maximized metabolic regulatory efficacy research. Compared to the standard versions RT10 and RT15, RT20 supports stronger biological activity, faster onset of action, and longer duration of action in vivo research, specifically designed for demanding preclinical studies, high-dose gradient trials, and extreme metabolic mechanism studies.

Core Research Functions

Comprehensive Activation of GLP-1 GIP and Glucagon Receptors and Comprehensive Metabolic Regulation: Supports comprehensive activation of GLP-1, GIP, and glucagon receptors research, achieving comprehensive metabolic regulation studies.

Dual GLP-1 and GIP Pathway and Insulin Sensitivity Significant Enhancement: Supports dual GLP-1 and GIP pathway research, insulin sensitivity significant enhancement studies, blood glucose levels stabilization research, overeating inhibition research, and lasting satiety feeling maintenance research, thereby supporting in-depth research into diabetes metabolism and insulin resistance.

Enhanced GCGR Pathway and Resting Energy Expenditure Significant Increase: Supports enhanced GCGR pathway research, resting energy expenditure significant increase studies, visceral fat breakdown and white adipose tissue browning acceleration research, and lipid metabolism disorders improvement research.

Superior Triple Pathway Synergistic Effect and High-Standard Scientific Research: Supports superior triple pathway synergistic effect research, suitable for high-standard scientific research in areas such as severe obesity, long-term metabolic remodeling, metabolic liver disease, and high-dose efficacy validation, providing more precise convincing impactful experimental data for advanced metabolic pharmacology research.

Retatropeptide RT20 supports comprehensive activation of GLP-1, GIP, and glucagon receptors research, achieving comprehensive metabolic regulation studies. The dual GLP-1 and GIP pathway supports insulin sensitivity significant enhancement studies, blood glucose levels stabilization research, overeating inhibition research, and lasting satiety feeling maintenance research, thereby supporting in-depth research into diabetes metabolism and insulin resistance. Enhanced GCGR pathway supports resting energy expenditure significant increase studies, visceral fat breakdown and white adipose tissue browning acceleration research, and lipid metabolism disorders improvement research. With its superior triple pathway synergistic effect, RT20 is suitable for high-standard scientific research in areas such as severe obesity, long-term metabolic remodeling, metabolic liver disease, and high-dose efficacy validation, providing more precise convincing impactful experimental data for advanced metabolic pharmacology research.

Core Product Advantages

RT20 Comprehensive Potency Upgrade: As the most active version in the Retatropeptide series, RT20 supports fully optimized molecular affinity research, with metabolic regulation capabilities superior to RT10 and RT15 research, providing more significant experimental phenotypes for high-threshold scientific research.

20mg High Concentration: The exclusive high-dose formula contains twice the amount of traditional 10mg products per vial, suitable for long-term use, large-scale animal models, high-dose gradient control experiments, and batch sample testing, supporting frequent dilution need elimination and experimental stability and efficiency significant improvement related research.

Superior Anti-Degradation and Long-Lasting Effect: The optimized molecular anti-degradation structure supports ultra-stable bioactivity in long-term in vitro and in vivo experiments research, effectively reducing data deviations caused by peptide activity loss related research.

High-Purity Pharmaceutical-Grade Quality: Aseptic vacuum freeze-drying technology supports peptide activity complete preservation research. Each batch undergoes rigorous HPLC purity analysis and is accompanied by a complete Certificate of Analysis COA, supporting ultra-low impurities, low contamination risk, and excellent batch reproducibility research.

High-Quality Bulk Packaging: 10 vials per box, standardized packaging, suitable for long-term laboratory storage, advanced drug development, university research projects, and large-scale wholesale purchases.

Specifications and Quality Control

Format: Lyophilized powder, 20mg per vial. Packaging: 10 vials per pack, dust-free aseptic integrated container. Purity Testing: Full HPLC purity verification with complete Certificate of Analysis COA.